Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

RHB Benedict, J DeLuca, G Phillips… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Cognitive and motor performance measures are commonly employed in multiple sclerosis
(MS) research, particularly when the purpose is to determine the efficacy of treatment. The …

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis

P Feys, I Lamers, G Francis, R Benedict… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Impaired manual dexterity is a frequently reported disability in people with multiple sclerosis
(MS) and is increasingly prevalent with worsening disease. While various tests and patient …

[PDF][PDF] Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota

F Cignarella, C Cantoni, L Ghezzi, A Salter, Y Dorsett… - Cell metabolism, 2018 - cell.com
Multiple sclerosis (MS) is more common in western countries with diet being a potential
contributing factor. Here we show that intermittent fasting (IF) ameliorated clinical course and …

[PDF][PDF] A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms

IY Choi, L Piccio, P Childress, B Bollman, A Ghosh… - Cell reports, 2016 - cell.com
Dietary interventions have not been effective in the treatment of multiple sclerosis (MS).
Here, we show that periodic 3-day cycles of a fasting mimicking diet (FMD) are effective in …

[HTML][HTML] Gait analysis methods: An overview of wearable and non-wearable systems, highlighting clinical applications

A Muro-De-La-Herran, B Garcia-Zapirain… - Sensors, 2014 - mdpi.com
This article presents a review of the methods used in recognition and analysis of the human
gait from three different approaches: image processing, floor sensors and sensors placed on …

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

MC Donohue, RA Sperling, DP Salmon… - JAMA …, 2014 - jamanetwork.com
Importance As Alzheimer disease (AD) research moves to intervene in presymptomatic
phases of the disease, we must develop outcome measures sensitive to the earliest disease …

[HTML][HTML] Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) …

S Meyer-Moock, YS Feng, M Maeurer, FW Dippel… - BMC neurology, 2014 - Springer
Background There are a number of instruments that describe severity and progression of
multiple sclerosis and they are increasingly used as endpoints to assess the effectiveness of …

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

RW Motl, JA Cohen, R Benedict… - Multiple Sclerosis …, 2017 - journals.sagepub.com
The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes
representatives from advocacy organizations, Food and Drug Administration (FDA) …

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox… - The Lancet, 2012 - thelancet.com
Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a
phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We …

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

AJ Coles, CL Twyman, DL Arnold, JA Cohen… - The lancet, 2012 - thelancet.com
Background The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in
previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess …